We are live on
!
Find out more
BM
Brandywine Managers Portfolio holdings
AUM
$170M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
+0.85%
1 Year Est. Return
+10.01%
3 Year Est. Return
+53.1%
5 Year Est. Return
+7.42%
10 Year Est. Return
+248.69%
AUM
$28.6M
AUM Growth
-$1.78M
(-5.9%)
Cap. Flow
-$13.2K
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
60.06%
Holding
41
New
2
Increased
3
Reduced
2
Closed
4
Top Buys
| 1 |
Prime Medicine
PRME
|
+$596K |
| 2 |
Mobileye
MBLY
|
+$397K |
| 3 |
CrowdStrike
CRWD
|
+$122K |
| 4 |
Guardant Health
GH
|
+$120K |
| 5 |
Twist Bioscience
TWST
|
+$97.7K |
Top Sells
| 1 |
Ionis Pharmaceuticals
IONS
|
+$374K |
| 2 |
Varonis Systems
VRNS
|
+$360K |
| 3 |
Beam Therapeutics
BEAM
|
+$224K |
| 4 |
SentinelOne
S
|
+$202K |
| 5 |
Seer Inc
SEER
|
+$119K |
Sector Composition
| 1 | Technology | 55.54% |
| 2 | Healthcare | 34.04% |
| 3 | Consumer Staples | 4.76% |
| 4 | Financials | 3.34% |
| 5 | Consumer Discretionary | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
UiPath
PATH
$6.23B
| $5.53M | 19.31% |
434,841
| – | – |
|
|
2
CrowdStrike
CRWD
$207B
| $3.02M | 10.55% |
114,720
+3,552
| +3% | +$122K |
|
3
Moderna
MRNA
$25.1B
| $1.71M | 5.97% |
9,510
| – | – |
|
4
Campbell Soup
CPB
$6.75B
| $1.36M | 4.76% |
24,014
| – | – |
|
5
Alnylam Pharmaceuticals
ALNY
$37.8B
| $1.1M | 3.83% |
4,608
| – | – |
|
6
Mastercard
MA
$487B
| $956K | 3.34% |
2,750
| – | – |
|
7
Intuitive Surgical
ISRG
$142B
| $927K | 3.24% |
3,495
| – | – |
|
8
Salesforce
CRM
$141B
| $917K | 3.2% |
6,913
| – | – |
|
9
Natera
NTRA
$38.6B
| $865K | 3.02% |
21,534
| – | – |
|
10
PagerDuty
PD
$821M
| $811K | 2.83% |
30,517
| – | – |
|
11
Zscaler
ZS
$23.7B
| $783K | 2.74% |
7,000
| – | – |
|
12
Okta
OKTA
$25.7B
| $700K | 2.45% |
10,248
| – | – |
|
13
Veeva Systems
VEEV
$32.1B
| $632K | 2.21% |
3,919
| – | – |
|
|
14
Prime Medicine
PRME
$582M
| $613K | 2.14% |
+32,977
| New | +$596K |
|
15
AbCellera Biologics
ABCL
$1.88B
| $577K | 2.02% |
56,976
| – | – |
|
16
Datadog
DDOG
$93.4B
| $529K | 1.85% |
7,200
| – | – |
|
17
Advanced Micro Devices
AMD
$817B
| $525K | 1.83% |
8,099
| – | – |
|
18
NVIDIA
NVDA
$5.02T
| $521K | 1.82% |
35,640
| – | – |
|
19
Palo Alto Networks
PANW
$289B
| $517K | 1.81% |
7,410
| – | – |
|
|
20
Twist Bioscience
TWST
$5.68B
| $499K | 1.74% |
20,970
+3,371
| +19% | +$97.7K |
|
21
Twilio
TWLO
$31.4B
| $479K | 1.67% |
9,782
| – | – |
|
22
Relay Therapeutics
RLAY
$4.22B
| $475K | 1.66% |
31,807
| – | – |
|
|
23
Mobileye
MBLY
$7.55B
| $458K | 1.6% |
+13,067
| New | +$397K |
|
|
24
Guardant Health
GH
$20.6B
| $433K | 1.51% |
15,933
+2,625
| +20% | +$120K |
|
25
10x Genomics
TXG
$5.65B
| $408K | 1.43% |
11,208
| – | – |
|
Similar funds
CF
DBFM
CAS
FH
RWFS
RFO
DWM
AGC
Brandywine Managers's Q4 2022 Portfolio in Review
As of Q4 2022, Brandywine Managers held 41 positions worth $28.6M, down 5.9% from $30.4M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Brandywine Managers's Q4 2022 filing shows 2 new, 3 increased, 2 reduced and 4 closed positions. Its largest new stake was Prime Medicine: 32,977 shares worth $613K. The largest sale was Ionis Pharmaceuticals, an estimated $374K.
By sector, the portfolio is most concentrated in Technology at 56% of assets, down from 61% a quarter earlier, followed by Healthcare and Consumer Staples.
- Brandywine Managers's largest Q4 2022 buy was Prime Medicine: 32,977 shares worth $613K.
- Brandywine Managers added most to CrowdStrike in Q4 2022, an estimated $122K increase.
- Brandywine Managers's biggest Q4 2022 reduction was Beam Therapeutics, cutting an estimated $224K.
- Brandywine Managers fully exited Ionis Pharmaceuticals in Q4 2022, selling an estimated $374K.
- Brandywine Managers's ten largest holdings make up 60% of its $28.6M portfolio in Q4 2022.
- Brandywine Managers opened 2 new positions and closed 4 in Q4 2022.
- Brandywine Managers's portfolio value fell 5.9% quarter-over-quarter to $28.6M.
Based on Brandywine Managers's 13F filing for Q4 2022, filed 14 Feb 2023.